Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 31316003.
- Also identified by DOI 10.1126/scitranslmed.aau0416 and PMC identifier 7402218.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
LB100 does not sensitize CML stem cells to tyrosine kinase inhibitor-induced apoptosis.
Medical subject headings
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive